Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29352661 | 1.00 | L3MBTL1 (0.45) | L3MBTL1HTR6NR1H2EPHX1NR3C2 | |
| SCHEMBL29350216 | 0.86 | L3MBTL1 (0.45) | L3MBTL1HTR6NR1H2EPHX1PDE10A | |
| SCHEMBL15777230 | 0.86 | L3MBTL1 (0.45) | L3MBTL1HTR6NR1H2EPHX1JAK2 | |
| SCHEMBL29352824 | 0.86 | L3MBTL1 (0.45) | L3MBTL1HTR6NR1H2EPHX1JAK2 | |
| SCHEMBL15777186 | 0.86 | L3MBTL1 (0.45) | L3MBTL1HTR6NR1H2EPHX1PDE10A | |
| SCHEMBL30458273 | 0.85 | L3MBTL1 (0.51) | L3MBTL1HTR6EPHX1PDE10AADAM17 | |
| SCHEMBL18036681 | 0.85 | L3MBTL1 (0.51) | L3MBTL1HTR6EPHX1PDE10AADAM17 | |
| SCHEMBL29354266 | 0.85 | L3MBTL1 (0.44) | L3MBTL1HTR6NR1H2EPHX1PDE10A | |
| SCHEMBL15778086 | 0.85 | L3MBTL1 (0.44) | L3MBTL1HTR6NR1H2EPHX1PDE10A | |
| SCHEMBL30458168 | 0.84 | L3MBTL1 (0.47) | L3MBTL1HTR6EPHX1PDE10AADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408064-A1 | RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF | GENETOLEAD INC. (CA) | 2024-12-12 | — | — | US | disclosed |
| WO-2023060362-A1 | RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF | GENETOLEAD INC. (CA) | 2023-04-20 | — | — | WO | disclosed |
| CN-108341799-B | Novel indole derivatives for the treatment of cancer, viral infections and lung diseases | 生物控制术公司 | 2022-01-25 | — | — | CN | disclosed |
| US-10851054-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | BIOKINESIS (FR) | 2020-12-01 | — | — | US | disclosed |
| US-10851054-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | BIOKINESIS (FR) | 2020-12-01 | — | — | US | disclosed |
| US-20190169124-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | DIACCURATE (FR) | 2019-06-06 | — | — | US | disclosed |
| US-20190169124-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | DIACCURATE (FR) | 2019-06-06 | — | — | US | disclosed |
| US-10189782-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | BIOKINESIS (FR) | 2019-01-29 | — | — | US | disclosed |
| US-10189782-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | BIOKINESIS (FR) | 2019-01-29 | — | — | US | disclosed |
| US-20170233342-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | DIACCURATE (FR) | 2017-08-17 | — | — | US | disclosed |
| US-9643923-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | BIOKINESIS (FR) | 2017-05-09 | — | — | US | disclosed |
| US-9643923-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | BIOKINESIS (FR) | 2017-05-09 | — | — | US | disclosed |
| US-20150307450-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-10-29 | — | — | US | disclosed |
| US-20150307450-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-10-29 | — | — | US | disclosed |
| EP-2928864-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | Biokinesis (FR) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014086964-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | BIOKINESIS (FR) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014086964-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | BIOKINESIS (FR) | 2014-06-12 | — | — | WO | disclosed |
| EP-2334681-A1 | 1,2,3,6-TETRAHYDROAZEPINO[4,5-B]INDOLE-5-CARBOXYLATE NUCLEAR RECEPTOR INHIBITORS | Wyeth LLC (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20110039824-A1 | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors | WYETH (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2010036362-A1 | 1,2,3,6-TETRAHYDROAZEPINO[4,5-B]INDOLE-5-CARBOXYLATE NUCLEAR RECEPTOR INHIBITORS | WYETH (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039824-A1 | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors | NR1H4, NR1H2, NR1I3 | L3MBTL1 4219/4885HTR6 150/4885NR1H2 2/4885 |
| US-20190169124-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | IDO2, IDO1, ING2 | L3MBTL1 1926/4885HTR6 495/4885NR1H2 1078/4885 |
| US-20150307450-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | IDO2, IDO1, ING2 | L3MBTL1 1926/4885HTR6 495/4885NR1H2 1078/4885 |
| US-20240408064-A1 | RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | L3MBTL1 2077/4885HTR6 4861/4885NR1H2 2184/4885 |
| US-10189782-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | IDO2, IDO1, ING2 | L3MBTL1 1548/4885HTR6 513/4885NR1H2 662/4885 |
| US-20170233342-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | IDO2, IDO1, ING2 | L3MBTL1 1926/4885HTR6 495/4885NR1H2 1078/4885 |
| US-10851054-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | IDO2, IDO1, ING2 | L3MBTL1 1548/4885HTR6 513/4885NR1H2 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.